Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 5/20 | 0.43 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.43 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.43 |
| ▸ | GGH | Q92820 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 2/20 | 0.37 |
| ▸ | FNTB | P49356 | 2/20 | 0.37 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22111315 | 1.00 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLAGGHALDH1A1 | |
| SCHEMBL12118214 | 1.00 | FOLH1 (0.43) | FOLH1NAALAD2RIMKLAGGHALDH1A1 | |
| SCHEMBL21440833 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLAFNTAFNTB | |
| SCHEMBL21242989 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLAFNTAFNTB | |
| SCHEMBL12118226 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLAFNTAFNTB | |
| SCHEMBL13377667 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLAFNTAFNTB | |
| SCHEMBL21242721 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLAFNTAFNTB | |
| SCHEMBL21440846 | 0.89 | NOD1 (0.53) | FOLH1NAALAD2RIMKLAFNTAFNTB | |
| SCHEMBL12734745 | 0.86 | FOLH1 (0.34) | FOLH1NAALAD2RIMKLAGGHALDH1A1 | |
| SCHEMBL13475050 | 0.84 | ALDH1A1 (0.41) | FOLH1NAALAD2RIMKLAGGHALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209028-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-06-27 | — | — | US | disclosed |
| WO-2024133739-A1 | AMYLIN RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2024-06-27 | — | — | WO | disclosed |
| US-20240209028-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-06-27 | — | — | US | disclosed |
| WO-2024094747-A1 | CNP COMPOUNDS | NOVO NORDISK A/S (DK) | 2024-05-10 | — | — | WO | disclosed |
| EP-3250191-B1 | TABLETS COMPRISING GLP-1 AGONIST AND ENTERIC COATING | NOVO NORDISK AS (DK) | 2024-01-17 | — | — | EP | disclosed |
| US-20230330189-A1 | ACYLATED GLP-1 DERIVATIVE | Sciwind Biosciences Co., Ltd. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230330189-A1 | ACYLATED GLP-1 DERIVATIVE | Sciwind Biosciences Co., Ltd. (CN) | 2023-10-19 | — | — | US | disclosed |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-09-21 | — | — | US | disclosed |
| WO-2023139106-A2 | LONG-ACTING GIPR ANTAGONISTS | NOVO NORDISK A/S (DK) | 2023-07-27 | — | — | WO | disclosed |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | PEP2TANGO THERAPEUTICS INC. | 2023-06-29 | — | — | US | disclosed |
| US-20090156478-A1 | Acylated GLP-1 Compounds | NOVO NORDISK A/S (DK) | 2009-06-18 | — | — | US | disclosed |
| US-20090105118-A1 | Preparation and applications of novel complexes made by gamma-polyglutamic acid and cisplatin | YE HAIFENG | 2009-04-23 | — | — | US | disclosed |
| US-20090092664-A1 | POLYMER-METAL CHELATOR CONJUGATES AND USES THEREOF | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2009-04-09 | — | — | US | disclosed |
| US-20080262412-A1 | Internal medical devices for delivery of therapeutic agent in conjunction with a source of electrical power | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-20080207507-A1 | Extended Glp-1 Compounds | NOVO NORDISK A/S (DK) | 2008-08-28 | — | — | US | disclosed |
| WO-2008023050-A1 | ACYLATED EXENDIN-4 COMPOUNDS | NOVO NORDISK A/S (DK) | 2008-02-28 | — | — | WO | disclosed |
| US-20070272119-A1 | Coating Composition, Coating Film, and Method of Reducing Underwater Friction | NIPPON PAINT CO., LTD. (JP) | 2007-11-29 | — | — | US | disclosed |
| US-20070178136-A1 | Medical devices for therapeutic agent delivery with polymeric regions that contain copolymers having both soft segments and uniform length hard segments | BOSTON SCIENTIFIC SCIMED, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070178136-A1 | Medical devices for therapeutic agent delivery with polymeric regions that contain copolymers having both soft segments and uniform length hard segments | BOSTON SCIENTIFIC SCIMED, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070099827-A1 | Sialogogue, oral composition and fool product containing the same | MEIJI SEIKA KAISHA, LTD. (JP) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207507-A1 | Extended Glp-1 Compounds | GLP1R, GIPR, IAPP | FOLH1 274/4885NAALAD2 485/4885RIMKLA 1572/4885 |
| US-20090156478-A1 | Acylated GLP-1 Compounds | GLP1R, GIPR, GCGR | FOLH1 450/4885NAALAD2 112/4885RIMKLA 742/4885 |
| US-20230203100-A1 | COMPOSITIONS INCLUDING MULTI-AGONIST PEPTIDES AND METHODS OF MANUFACTURE AND USE | IAPP, GPR119, GIPR | FOLH1 1596/4885NAALAD2 1715/4885RIMKLA 851/4885 |
| US-20240209028-A1 | CNP COMPOUNDS | NPPA, NPR1, NPR3 | FOLH1 562/4885NAALAD2 356/4885RIMKLA 1848/4885 |
| US-20070099827-A1 | Sialogogue, oral composition and fool product containing the same | FUCA1, PGA5, FUCA2 | FOLH1 276/4885NAALAD2 696/4885RIMKLA 1554/4885 |
| US-20090092664-A1 | POLYMER-METAL CHELATOR CONJUGATES AND USES THEREOF | FIBP, ENPEP, SLC30A6 | FOLH1 26/4885NAALAD2 255/4885RIMKLA 505/4885 |
| US-20230295260-A1 | GLP RECEPTOR AGONISTS | GLP1R, GIPR, NPY4R | FOLH1 2988/4885NAALAD2 493/4885RIMKLA 2945/4885 |
| US-20090105118-A1 | Preparation and applications of novel complexes made by gamma-polyglutamic acid and cisplatin | GGCT, POLG, FPGS | FOLH1 20/4885NAALAD2 381/4885RIMKLA 51/4885 |
| US-20230330189-A1 | ACYLATED GLP-1 DERIVATIVE | GLP1R, GIPR, IAPP | FOLH1 648/4885NAALAD2 247/4885RIMKLA 1548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.